伤寒Vi多糖菌苗的安全性和免疫效果研究  

Safety and Immune Efficacy of Salmonella typhi Vi Capsular Polysaccharide Vaccine

作　　者：谢广中[1] 辜清吾[2] 王秉瑞[3] 王立亚[4] 王洪飞[5] 丁兆松 杨耀 王薇媛[2] 王祥初[1] 

机构地区：[1]卫生部上海生物制品研究所,上海200052 [2]中国药品生物制品检定所 [3]卫生部兰州生物制品研究所 [4]卫生部北京生物制品研究所 [5]卫生部长春生物制品研究所 [6]卫生部武汉生物制品研究所 [7]卫生部成都生物制品研究所

出　　处：《中国生物制品学杂志》1998年第2期119-122,共4页Chinese Journal of Biologicals

摘　　要：对我国首次研究成功的伤寒Vi多糖菌酋进行了人体接种安全性、反应性、血清学效果和流行病学效果观察，各期观察达21万余人，结果证实伤寒Vi多糖茵茵安全世良好，反应轻微。血清学效果显示，30μg一次免疫，Vi抗体4倍增长可达91．6％。两次流行病学效果考核，按血培养伤寒杆菌阳性病例统计，保护率可达70％左右，茵茵的效果指数为3．29～3．49。该菌苗性质稳定，初免只需注射一针，替代现行菌体菌苗推广应用是完全可行的。The safety,reactivity,serological and epidemiological efficacy of Salmonellatyphi Vi capsular polysaccharide vaccine were studied in more than 210,000 volunteers.Theresult showed good safety and mild reaction of the vaccine.The Vi antibody level increasedby 4-folds in 91.6% of the volunteers after being immunized with one dose(30μg)of thevaccine.According to the result of blood sample cultrue for Salmonella typhi,the protectiverate of the vaccine reached about 70%,and the efficacy index of it was 3.29～3.49.The vaccine was stable and only a single dose is required for primary immunization.So it might bewidely used as a substitute for current Salmonella typhi whole cell vaccine.

关 键 词：伤寒 Vi多糖菌苗 血清学效果 安全性 

分 类 号：R516.301[医药卫生—内科学]